NurExone Biologic Inc

Redefining the future of regenerative medicine

NurExone Biologic Inc. is a biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries.

Oncolytics Biotech stock takes off after naming new CEO

Oncolytics Biotech (TSX:ONC), a clinical-stage oncology stock, adds more than 20 per cent after onboarding a new chief executive officer.

Datametrex acquires Arbutus Health and Wellness, expands Canadian healthcare footprint

Datametrex AI (TSXV:DM) announced the acquisition of Arbutus Health and Wellness Inc., a multidisciplinary medical clinic.
MediPharm Labs - MediPharm Labs Australia facility.

What is going on with MediPharm Labs?

MediPharm Labs (TSX:LABS) has begun production for its novel cannabis metered dose inhalers (MDIs) tailored for the EU and UK markets.
Algernon Pharmaceuticals Inc.

Algernon closes NoBrainer acquisition

Algernon Pharmaceuticals (CSE:AGN) has officially closed its acquisition of NoBrainer Imaging Centres, Inc.
Cannabis Report above an image of cannabis

StockTalk | Cannabis Report: Shareholders lawyer up and go rogue

Several TSX healthcare stocks that cater to various aspects of the healthcare market are listed on the TSX, including notable cannabis stocks.

Quipt Home Medical addresses hostile takeover bid

Quipt Home Medical (TSX:QIPT) acknowledges a hostile takeover proposal from Forager Capital Management at C$3.10 per share.
The Market Online Video

Developing new therapies for traumatic central nervous system injuries

NurExone Biologic Inc. , an innovative biotech company pioneering exosome based therapies designed to help patients...
ai generated stock image

Buzz on the Bullboards: Quarterly reports and company mergers

This week also marks the heart of quarterly earnings season, when companies disclose their financial and operational performance.

Trump revives effort to lower drug costs with new executive order

U.S. President Donald Trump announced on Monday that he will sign an executive order aimed at reducing the costs of certain medications
Willow Biosciences logo

Willow Biosciences reports Q1 2025 earnings on the eve of its major reorganization

Willow Biosciences (TSX:WLLW) has announced its financial results for its Q1 ended March 31, 2025, showing a turnaround in its performance.

Ocumetics’ corrective lens meets key milestone before human trials

Ocumetics (TSXV:OTC), an ophthalmic solutions provider, meets another milestone with its intraocular lens technology.

Buzz on the Bullboards: From oil fields to labs, TSX Stories making waves

Several TSX and TSX Venture-listed companies made significant announcements that could shape their near-term trajectories.
Willow Biosciences logo

Willow Biosciences up 200% on news of transformation into Atlas Energy Corp.

Willow Biosciences (TSX:WLLW) unveiled a C$30 million financing plan, reorganization that will see the company emerge as Atlas Energy Corp.

Innocan secures Mexican patent for topical pain-relief technology

Pharmaceutical biotechnology company Innocan Pharma (CSE:INNO) announced a significant milestone in its global intellectual property strategy.
Rocket ship shooting from light bulb investment concept

The 5-Minute Investor Podcast, Ep. 9: Cancer drugs and corner stores

Welcome to episode 9 of The 5-Minute Investor Podcast, featuring Stockhouse columnists Jonathon Brown and Trevor Abes.